Home

FDF / DRUG PRODUCTS SERVICES in APAC

The Nanjing site specializes in the development and production of solid and liquid pharmaceutical forms, both sterile and non-sterile.

China APAC

FDF / DRUG PRODUCTS SERVICES in APAC

The Nanjing site specializes in the development and production of solid and liquid pharmaceutical forms, both sterile and non-sterile.

FDF / DRUG PRODUCTS SERVICES  in APAC

About the plant

The Nanjing manufacturing site of Unither Pharmaceuticals is located in Jiangsu Province, China, and forms part of the group’s global network of contract development and manufacturing organizations (CDMOs). The facility specializes in the development and production of pharmaceutical products in both solid and liquid dosage forms, including sterile formulations.

The site has strong expertise in sterile single-dose liquid products manufactured using Blow-Fill-Seal (BFS) technology. This aseptic process integrates container forming, filling, and sealing in a single operation and is widely used for ophthalmic and respiratory solutions requiring high sterility assurance. The Nanjing facility focuses particularly on ophthalmology and ENT products, supplying pharmaceutical companies in China and supporting access to international markets.

 

In addition to sterile liquid manufacturing, the plant also supports solid dosage forms and provides development services such as formulation development, process optimization, and analytical quality control testing. Operating under Chinese GMP regulations and aligned with international pharmaceutical quality standards, the Nanjing facility plays a strategic role in Unither’s expansion in Asia and in supplying safe, high-quality pharmaceutical products to regional and global healthcare markets.


Compliance
  • EMA (EU GMP)
  • FDA (cGMP)
  • NMPA (China GMP)

Activity
  • Oral solids / OSD, Sterile forms (ophtalmic, nasal, otic), Granules / Pellets, Fill&Finish, BFS (Blow Fill Seal) ampoules, FDF / DRUG PRODUCTS, SERVICES manufacturing

Features
  • Uses: Investigational, Commercial (Phase IV), Phase I, Phase II, Phase III, Human
  • Toxicity (OEB classification): N/A
  • Controlled substance: Lowest potential for abuse
  • BSL: N/A
  • Therapeutic areas: (R) Respiratory system, (S) Sensory organs
  • Markets: FDA (USA), EMA (EU), NMPA (China)

Batch Size / Reactor
  • Medium, Large

Services
  • Development services, Manufacturing services, Analytical / QC services, Formulation / Galenic design, Process development, Process optimization, Stability studies design, Tech transfer, Pilot plant, Formulation mixing, Scale-up, Batch records, Analytical methods development, Analytical methods validation, Stability tests, Identity, Content, Purity / Potency, Drug Product – Liquid, Drug Product – Solid, API / Excipient – Liquid, API / Excipient – Solid

Contact us

If you have any questions or suggestions, click here. We will be happy to assist you.

Want to see all the information?

Unleash the full power of MAI CDMO

Register for free

Cambrex
ReigJofre
53Biologics
VIVUNT
Lannett
Shilpa Biologicals